ZymoGenetics And Serono Begin Phase 2 Clinical Trial With Atacicept In Rheumatoid Arthritis

... ZymoGenetics, Inc. (Nasdaq: ZGEN) and Serono (NYSE: SRA; virt-x: SEO) today announced the start of a Phase 2 clinical trial in which atacicept therapy will be evaluated in patients with rheumatoid arthritis (RA). The randomized, double-blind, multi-center study will investigate the efficacy of atacicept in patients with an inadequate response to prior treatment with TNF inhibitors. [click link for full article] ...